Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02578602 · ClinicalTrials.gov registry record · Phase 1
MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer
A Phase 1 study of Advanced Adult Hepatocellular Carcinoma and Adult Hepatocellular Carcinoma, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT02578602 is a Phase 1 study of Advanced Adult Hepatocellular Carcinoma and Adult Hepatocellular Carcinoma that has completed, run by University of Southern California. The registered enrollment target is 26 participants, roughly in line with the 28-participant average among 3 other Advanced Adult Hepatocellular Carcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT02578602, a Phase 1 study of Advanced Adult Hepatocellular Carcinoma and Adult Hepatocellular Carcinoma, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot clinical trial studies magnetic resonance imaging (MRI) with gadoxetate disodium in measuring tumors in patients with liver cancer. Diagnostic procedures, such as MRI with gadoxetate disodium, may help find and diagnose liver cancer and find out how far the disease has spread. It is not yet known whether MRI with gadoxetate disodium provides a more precise measurement of liver tumors than standard computed tomography (CT).
Conditions Studied
Interventions
- DEVICE Magnetic Resonance Imaging
- DRUG Gadoxetate Disodium
Study Locations (1)
California
- USC / Norris Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2010-10 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02578602
The ClinicalTrials.gov registry entry for NCT02578602 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 28-participant average among 3 other Advanced Adult Hepatocellular Carcinoma trials with a reported enrollment target. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Advanced Adult Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT02578602 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02578602 about?
NCT02578602 is a clinical study titled "MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer". This pilot clinical trial studies magnetic resonance imaging (MRI) with gadoxetate disodium in measuring tumors in patients with liver cancer. Diagnostic procedures, such as MRI with gadoxetate disodium, may help find and diagnose liver cancer and find out how far the disease has spread. It is not y...
What is the current status of trial NCT02578602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2010-10. Estimated completion is 2015-06.
What conditions does trial NCT02578602 study?
This clinical trial studies the following conditions: Advanced Adult Hepatocellular Carcinoma, Adult Hepatocellular Carcinoma, BCLC Stage B Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage 0 Adult Hepatocellular Carcinoma.
What interventions are being tested in trial NCT02578602?
The interventions under investigation include: Magnetic Resonance Imaging (DEVICE), Gadoxetate Disodium (DRUG).
Who is sponsoring clinical trial NCT02578602?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02578602 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Adult Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
COMPLETED · Phase 1
-
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
COMPLETED · Phase 1
-
Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
COMPLETED · NA
Explore more on PlainTrial
Advanced Adult Hepatocellular Carcinoma
All registered trials for this condition
Adult Hepatocellular Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.